Neurocrine Biosciences, Inc.
NASDAQNeurocrine Biosciences has taken a sharp hit after its Q2 print, falling 10.2% on Friday to $166.58 — yet the Street has responded not by retreating, but by lifting targets almost across the board. The earnings reaction is the story this week. The stock fell 7.9% on July 31, adding to a 5.2% weekly decline, erasing the run-up that had carried it to a multi-month high heading into…
NBIX short interest surges 21.8% in one week to 5.3% of float, as stock rallies ahead of earnings.
Snapshot as of 6 Aug 2026
Neurocrine Biosciences has taken a sharp hit after its Q2 print, falling 10.2% on Friday to $166.58 — yet the Street has responded not by retreating, but by lifting targets almost across the board. The earnings…
Neurocrine Biosciences heads into tonight's Q2 earnings report with analysts raising targets, the stock near a multi-month high, and short sellers in retreat — a setup where the bull case is already partly priced…
NBIX heads into the week with an interesting split: Goldman Sachs reinstated coverage with a Buy and a $213 target on the same day the stock fell nearly 4%. The analyst activity has been firmly bullish. Goldman's…
NBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction. The…
Neurocrine Biosciences heads into its May 5 Q1 results with a notable and accelerating build in short positions — the most distinctive feature of the current setup. Short interest has climbed sharply over the past…
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NBIX — free to start on ORTEX.
Sign up for free →Open NBIX on ORTEX